Pharming Reports Positive Phase II Leniolisib Data

Pharming reported Phase II topline data for leniolisib in genetically identifiable PIDs with immune dysregulation, including reductions in spleen volume and trends in pulmonary function. Separate CVID Phase II topline data are expected in November.